CHJ.77621
Acetylcholinesterase human
--
--
Ordering
Available Variants10 μg
CHJ.77621-10μg
Price
€390.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 μg | CHJ.77621-10μg | €390.40 |
recombinant, expressed in HEK 293 cells, lyophilized powder, ≥1,000 units/mg protein (BCA)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| CAS Number | 9000-81-1 |
|---|---|
| UNSPSC Code | 12352204 |
| NACRES | NA.32 |
| EC Number | 3.1.1.7 (BRENDA, IUBMB) |
| MDL number | MFCD00081268 |
| Specific activity | ≥1,000 units/mg protein (BCA) |
| Recombinant | expressed in HEK 293 cells |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Acetylcholinesterase human, also known as AChE, is a crucial enzyme involved in the breakdown of the neurotransmitter acetylcholine. With a CAS number of 9000-81-1, this enzyme plays a vital role in the nervous system by terminating the signal transmission at the synapse. Acetylcholinesterase human is primarily found in the neuromuscular junctions and cholinergic synapses, where it rapidly hydrolyzes acetylcholine into choline and acetate, thereby regulating the duration and intensity of neurotransmission. The enzymes activity is essential for maintaining proper muscle function and cognitive processes, and its dysfunction has been implicated in various neurological disorders, including Alzheimers disease and myasthenia gravis. As a result, acetylcholinesterase human has become a significant target for the development of therapeutic agents aimed at treating these conditions.
